Clinical-stage biotechnology company developing therapies for serious immune and inflammatory diseases.
Vera Therapeutics, Inc. is a biotechnology company in the clinical stage, dedicated to advancing therapeutic options for patients grappling with severe immunological disorders across the United States. At the forefront of its pipeline is atacicept, a promising fusion protein administered via subcutaneous injection. Currently undergoing Phase IIb clinical trials, atacicept targets immunoglobulin A nephropathy, aiming to address significant unmet medical needs in this patient population.
In addition to atacicept, Vera Therapeutics is actively developing MAU868, a monoclonal antibody designed to combat BK viremia infections. This innovative treatment is progressing through Phase 2 clinical trials, showcasing the company's commitment to expanding its therapeutic portfolio and addressing critical medical challenges.
Founded in 2016 under the name Trucode Gene Repair, Inc., Vera Therapeutics rebranded in April 2020 to reflect its strategic focus on therapeutic advancements in immunological diseases. Headquartered in Brisbane, California, the company leverages its robust research and development capabilities to propel advancements in biotechnology, with a mission to transform patient care through innovative treatments and meaningful clinical outcomes.
Vera Therapeutics collaborates with leading experts and institutions in the field of immunology, fostering partnerships aimed at accelerating the development and commercialization of novel therapies. With a foundation rooted in scientific innovation and patient-centric research, the company continues to forge ahead in its quest to deliver transformative therapies for patients in need.